Form 4: Neurocrine Biosciences Director Shalini Sharp Reports Stock Option and Restricted Stock Unit Grant

Director Shalini Sharp reports acquisition of stock options and restricted stock units in Neurocrine Biosciences.

Summary

• On May 22, 2024, Shalini Sharp, a director of Neurocrine Biosciences Inc. (NBIX), reported the acquisition of derivative securities.
• Sharp acquired 2,982 non-qualified stock options with an exercise price of $139.43, vesting in 12 monthly installments starting June 22, 2024, and expiring on May 22, 2034.
• Sharp also acquired 1,435 restricted stock units (RSUs), each representing the right to receive one share of Neurocrine Biosciences common stock upon vesting, which will occur in full on May 22, 2025.
• Following these transactions, Sharp directly owns 2,982 non-qualified stock options and 1,435 restricted stock units.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options and RSUs to a director is a common practice and generally viewed as a positive sign of alignment with shareholder interests. There are no explicitly negative indicators.

Positives

• The acquisition of stock options and restricted stock units by a director signals confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedules for the RSUs and stock options suggest a multi-year commitment.

Industry Context

Stock option and RSU grants are common practices in the biotechnology industry to incentivize and retain key personnel, aligning their interests with those of the shareholders.

Comparison to Industry Standards

• Stock option grants to directors are a standard practice in the biotech industry, similar to companies like Amgen (AMGN) and Gilead Sciences (GILD).
• The vesting schedule of 12 months for options and full vesting after one year for RSUs is also typical, aligning with industry norms for incentivizing long-term performance.

Stakeholder Impact

• The grant of stock options and RSUs aligns the director's interests with those of the shareholders, incentivizing them to work towards increasing shareholder value.
• Employees may view this as a positive sign, indicating the company's commitment to rewarding its leadership.

Key Dates